MK-2206 hydrochloride - CAS 1032349-77-1
Catalog number: 1032349-77-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C25H22ClN5O
Molecular Weight:
443.93
COA:
Inquire
Targets:
Akt
Description:
MK-2206 hydrochloride is the hydrochloride form of MK-2206, which is an allosteric inhibitor of Akt and an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B). It has potential antineoplastic activity. It exhibits anticancer chemotherapeutic activity in a variety of in vitro cancer models. It inhibits tumor growth in animal models of nasopharyngeal cancer.
Purity:
>98 %
Appearance:
Off-white powder
Synonyms:
MK-2206 hydrochloride; MK 2206 hydrochloride; 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one hydrochloride;MK2206 hydrochloride
Solubility:
Soluble in DMSO, water with 1 eq. of acid
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
MK-2206 hydrochloride has potential antineoplastic activity.
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
LFYOZCBFOSSLNJ-UHFFFAOYSA-N
InChI:
InChI=1S/C25H21N5O.ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);1H
Canonical SMILES:
C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl
1.Autophagy protects chondrocytes from glucocorticoids-induced apoptosis via ROS/Akt/FOXO3 signaling.
Shen C;Cai GQ;Peng JP;Chen XD Osteoarthritis Cartilage. 2015 Dec;23(12):2279-2287. doi: 10.1016/j.joca.2015.06.020. Epub 2015 Jul 9.
OBJECTIVE: ;Glucocorticoids (GCs) have been widely used in the management of osteoarthritis (OA) and rheumatoid arthritis (RA). Nevertheless, there has been some concern about their ability of increasing reactive oxygen species (ROS) in the cartilage. Forkhead-box class O (FOXO) transcription factors have been proved to have a protective role in chondrocytes through regulation of autophagy and defending oxidative stress. The objective of this study was to investigate the role of FOXO3 in Dex-induce up-regulation of ROS.;DESIGN: ;Healthy cartilages debris from six patients were used for chondrocytes culture. After the treatment of dexamethasone (Dex), the ROS levels, autophagic flux, the expression of FOXO3 in chondrocytes were measured. RNA interference technique was also used to determine the role of FOXO3 in Dex-induced autophagy. The metabolism of the extra-cellular matrix was also investigated.;THE RESULTS: ;Dex increased intracellular ROS level, the expression of Akt, FOXO3 as well as autophagy flux in human chondrocytes. The expression of aggrecanases also increased after the treatment of Dex. Catalase, the ROS scavenger, suppressed Dex-induced up-regulation of autophagy flux and expression of aggrecanases and Akt.
2.Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy.
Cong L;Xia ZK;Yang RY Arch Pharm (Weinheim). 2014 Sep;347(9):609-15. doi: 10.1002/ardp.201400116. Epub 2014 Jun 11.
Scleroderma (systemic sclerosis) is a connective tissue disease that affects various organ systems; the treatment of scleroderma is still difficult and remains a challenge to the clinician. Recently, kinase inhibitors have shown great potential against fibrotic diseases and, specifically, the transforming growth factor-β receptor (TGF-βR) was found as a new and promising target for scleroderma therapy. In the current study, we propose that the large pool of existing kinase inhibitors could be exploited for inhibiting the TGF-βR to suppress scleroderma. In this respect, we developed a modeling protocol to systematically profile the inhibitory activities of 169 commercially available kinase inhibitors against the TGF-βR, from which five promising candidates were selected and tested using a standard kinase assay protocol. Consequently, two molecular entities, namely the PKB inhibitor MK-2206 and the mTOR C1/C2 inhibitor AZD8055, showed high potency when bound to the TGF-βR, with IC50 values of 97 and 86 nM, respectively, which are close to those of the recently developed TGF-βR selective inhibitors SB525334 and LY2157299 (IC50 = 14.3 and 56 nM, respectively). We also performed atomistic molecular dynamics simulations and post-molecular mechanics/Poisson-Boltzmann surface area analyses to dissect the structural basis and energetic properties of intermolecular interactions between the TGF-βR kinase domain and these potent compounds, highlighting intensive nonbonded networks across the tightly packed interface of non-cognate TGF-βR-inhibitor complexes.
3.Insulin receptor substrate 2: a bridge between Hippo and AKT pathways.
Jeong SH;Lim DS BMB Rep. 2018 May;51(5):209-210.
NAFLD induces the development of advanced liver diseases such as NASH and liver cancer. Therefore, understanding the mechanism of NAFLD development is critical for its prevention and treatment. Ablation of PTEN or Hippo pathway components induces liver cancer in a murine model by hyperactive AKT or YAP/TAZ, respectively. Although the regulation of these two pathways occurs in the same hepatocyte, the details of crosstalk between Hippo-YAP/TAZ and PTEN-AKT pathways in liver homeostasis and tumorigenesis still remain unclear. Here, we found that depletion of both PTEN and SAV1 in liver promotes spontaneous NAFLD and liver cancer through hyperactive AKT via YAP/TAZmediated up-regulation of IRS2 transcription. Conversely, NAFLD is rescued by both ablation of YAP/TAZ and activation of the Hippo pathway. Furthermore, human HCC patients with NAFLD showed strong correlation between YAP/TAZ and IRS2 or phospho-AKT expression. Finally, the inhibition of AKT by MK-2206 treatment attenuates NAFLD development and tumorigenesis. Our findings indicate that Hippo pathway interacts with AKT signaling during the intervention with IRS2 to prevent NAFLD and liver cancer. [BMB Reports 2018; 51(5): 209-210].
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Akt Products


CAS 552325-16-3 A-443654

A-443654
(CAS: 552325-16-3)

A-443654 is a potent small-molecule inhibitor of all three Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines test...

CAS 276680-69-4 Akt/SKG Substrate Peptide

Akt/SKG Substrate Peptide
(CAS: 276680-69-4)

Akt/SKG Substrate Peptide is a synthetic peptide and used as a substrate for Akt/PKB. It could not be phosphorylated by MAP kinase or p70 S6 kinase activated pr...

SC79
(CAS: 305834-79-1)

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

CAS 522-17-8 Deguelin

Deguelin
(CAS: 522-17-8)

Deguelin is a naturally occurring rotenoid, is known to be an Akt inhibitor and to have an anti-tumor effect on several cancers.

CAS 1047644-62-1 Afuresertib

Afuresertib
(CAS: 1047644-62-1)

Afuresertib, also known as GSK2110183,  is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineo...

CAS 28755-03-5 3CAI

3CAI
(CAS: 28755-03-5)

3CAI is an orally active, potent and specific allosteric inhibitor of Akt1 and Akt2 that directly binds to Ak1 and Akt2 in an ATP noncompetitive manner.

CAS 1047634-65-0 Uprosertib

Uprosertib
(CAS: 1047634-65-0)

Uprosertib, also known as GSK2141795 and GSK795, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potentia...

CAS 1056901-62-2 AT13148

AT13148
(CAS: 1056901-62-2)

AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT...

Quick Inquiry

Verification code

Featured Items